Tag: Deruxtecan

As a potent antibody-drug conjugate, deruxtecan (brand name Enhertu) requires a precise intravenous (IV) administration protocol to deliver its therapeutic payload effectively to cancer cells. Understanding how is deruxtecan administered is critical for both patients and healthcare providers to ensure proper treatment and safety.

First approved by the U.S. Food and Drug Administration (FDA) in 2019 as a component of the drug Enhertu, deruxtecan serves as the highly potent cytotoxic payload within several advanced antibody-drug conjugates (ADCs). These conjugates, which specifically target cancer cells, represent a major advancement in targeted chemotherapy by delivering a powerful cell-killing agent directly to the tumor. The question, 'what does deruxtecan do?', is fundamentally about understanding this sophisticated delivery and attack system.

Over two decades, antibody-drug conjugates (ADCs) have transformed targeted cancer therapy, and the next-generation platform using a **DXd drug** as a payload is at the forefront of this innovation. This technology, pioneered by Daiichi Sankyo, is built around a potent topoisomerase I inhibitor, designed to precisely deliver chemotherapy to cancer cells while minimizing systemic harm.

In recent clinical trials, the targeted drug trastuzumab deruxtecan (Enhertu) demonstrated a 72% improvement in progression-free survival for certain patients with HER2-positive metastatic breast cancer compared to a different therapy. This innovative medication, which incorporates the chemotherapy payload **Deruxtecan**, represents a significant advancement in oncology by selectively delivering potent treatment directly to cancer cells.